To investigate why responses of mast cells to antigen-induced IgE receptor (FcεRI) aggregation depend nonlinearly on antigen dose, we characterized a new artificial ligand, DF3, through complementary modeling and experimentation. This ligand is a stable trimer of peptides derived from bacteriophage T4 fibritin, each conjugated to a hapten (DNP). We found low and high doses of DF3 at which degranulation of mast cells sensitized with DNP-specific IgE is minimal, but ligand-induced receptor aggregation is comparable to aggregation at an intermediate dose, optimal for degranulation. This finding makes DF3 an ideal reagent for studying the balance of negative and positive signaling in the FcεRI pathway. We find that the lipid phosphatase SHIP and the protein tyrosine phosphatase SHP-1 negatively regulate mast cell degranulation over all doses considered. In contrast, SHP-2 promotes degranulation. With high DF3 doses, relatively rapid recruitment of SHIP to the plasma membrane may explain the reduced degranulation response. Our results demonstrate that optimal secretory responses of mast cells depend on the formation of receptor aggregates that promote sufficient positive signaling by Syk to override phosphatase-mediated negative regulatory signals.
To investigate why responses of mast cells to antigen-induced IgE receptor (FcεRI) aggregation depend nonlinearly on antigen dose, we characterized a new artificial ligand, DF3, through complementary modeling and experimentation. This ligand is a stable trimer of peptides derived from bacteriophage T4 fibritin, each conjugated to a hapten (DNP). We found low and high doses of DF3 at which degranulation of mast cells sensitized with DNP-specific IgE is minimal, but ligand-induced receptor aggregation is comparable to aggregation at an intermediate dose, optimal for degranulation. This finding makes DF3 an ideal reagent for studying the balance of negative and positive signaling in the FcεRI pathway. We find that the lipid phosphatase SHIP and the protein tyrosine phosphatase SHP-1 negatively regulate mast cell degranulation over all doses considered. In contrast, SHP-2 promotes degranulation. With high DF3 doses, relatively rapid recruitment of SHIP to the plasma membrane may explain the reduced degranulation response. Our results demonstrate that optimal secretory responses of mast cells depend on the formation of receptor aggregates that promote sufficient positive signaling by Syk to override phosphatase-mediated negative regulatory signals.
Mast cells
and basophils trigger
allergic reactions when polyvalent antigens cross-link IgE–FcεRI
complexes on the cell surface. Signaling begins with phosphorylation
of FcεRIβ and FcεRIγ subunit ITAMs (immunoreceptor
tyrosine-based activation motifs), which in turn recruit downstream
regulatory proteins for signal propagation and regulation. FcεRI
signaling is a function of the properties of receptor aggregates formed
on the cell surface, including the size, spacing, and rate of internalization.[1−3] Valency is a particularly important factor controlling signaling
efficiency, as summarized in recent reviews.[4,5] Important
questions remain to be resolved about these relationships, particularly
regarding the links between signal regulation and the spatial arrangements
of receptor aggregates after cross-linking. The RBL-2H3tumor mast
cell is commonly used as a model system, typically by priming cells
with monoclonal IgE specific for a hapten. The best characterized
hapten is 2,4-dinitrophenyl (DNP),[6] where
cells sensitized with anti-DNPIgE are activated with ligands such
as DNP-conjugated bovine serum albumin (DNP–BSA) or ovalbumin.
With as many as 25 DNPs per protein carrier, these multivalent ligands
stimulate robust FcεRI signaling. However, their structural
heterogeneity, which arises from random coupling of DNP to lysine
residues, prevents high-precision control of receptor aggregation.
In addition, the unbound hapten groups of a DNP-conjugated protein
are not equivalent for binding IgE–FcεRI complexes on
cell surfaces because of steric constraints.[7,8] Another
unknown factor is the variability in affinity of IgE for haptens arising
from the influence of the hapten’s peptide environment.To address critical questions regarding the influence of the aggregation
state on FcεRI activation, our first step was the design of
a new DNP-based ligand with defined structure and valency. As a template,
we chose the foldon domain of fibritin from enterobacteria phage T4,
which spontaneously self-assembles into a stable trimer.[9,10] Fibritin trimerization occurs through β-hairpins in the foldon
domain; the foldon trimer is stabilized by hydrophobic amino acid
interactions, intermolecular salt bridges, and hydrogen bonds. We
synthesized a stable trivalent DNP ligand by attaching DNP to the
N-terminus of a peptide comprising the foldon domain via a flexible
linker and allowing the conjugated peptide to self-assemble. Structural
analysis predicts that each DNP in the trimer is available to engage
with IgEDNP–FcεRI complexes on the mast cell
surface. Optimal doses elicit robust mast cell responses that are
comparable to those achieved with DNP–BSA and other commonly
used DNP-conjugated carrier proteins. Moreover, degranulation responses
of RBL-2H3 cells to DF3 stimulation are characterized by a dose-dependent
bell-shaped curve.Because bell-shaped secretory response curves
are characteristic
of primary mast cells and basophils,[11] we
focused on the link between the receptor aggregation state and signaling
outcome. Dose-dependent differences in the DF3–IgE–FcεRI
aggregation state were characterized by equilibrium binding assays
and diffusion measurements. These data provided parameters for mathematical
predictions of receptor aggregate size in cells stimulated over a
range of ligand doses. Fundamental predictions of the model are the
presence of receptor aggregates at inhibitory doses and dose-dependent
differences in receptor aggregation kinetics. These predictions were
validated by fluorescence-based receptor cluster analysis and transmission
electron microscopy (TEM) imaging. In addition to characterization
of Syk, Lyn, and FcεRI ITAM phosphorylation, receptor internalization,
and calcium mobilization, we focused on phosphatases implicated in
FcεRI signal regulation. We show that the inositol phosphatase
SHIP, previously coined the “gatekeeper” of mast cell
degranulation,[12] colocalizes with receptors
to hold the system in check at both suboptimal and inhibitory ligand
doses. Two closely related tyrosine phosphatases, SHP-1 and SHP-2,
have opposing effects on mast cell degranulation, suggesting that
they act on distinct substrates. We propose that the ligand-induced
aggregation state is a critical factor for tipping the balance between
positive and negative signaling in the control of mast cell degranulation.
Results
and Discussion
Design of a Trivalent Ligand for Cross-Linking
DNP-Specific
IgE–FcεRI Complexes
A large body of preexisting
literature supports the concept that antigen–IgE–FcεRI
aggregate size is somehow a key component of mast cell activation.[13] Previous studies characterizing low-valency
ligands have depended on biochemistry techniques, such as gel filtration
chromatography and chemical cross-linking, to estimate the extent
of cross-linking and the size distributions of ligand–receptor
complexes.[1,14] Our goal was to reexamine these questions
through use of a new structurally defined ligand, computation, and
experimental measures of aggregation and signaling.To create
a structurally defined trivalent ligand for inducing IgEDNP–FcεRI aggregation, a peptide representing the C-terminus
of the T4 fibritin foldon domain was synthesized with a short peptide
linker and DNP conjugated at the N-terminus (Figure 1A of the Supporting Information). The foldon peptide self-assembles
into a stable trimer in aqueous buffer.[15,16] We refer to
this cross-linking reagent as DF3. A fluorescent 5FAM tag was conjugated
to the C-terminus for some applications (DF35FAM), and
the stability of 5FAM-labeled DF3 was verified (Figure 1B,C of the Supporting Information).Figure 1A presents a model for the three-dimensional
(3D) atomic structure of DF3. Structural models of IgEDNP–FcεRI aggregates that may be induced by DF3 (Figure 1B,C) were constructed on the basis of available
structural knowledge, such as information about the molecular basis
for the high-affinity interaction of IgE with the FcεRIα
ectodomain.[17] The distance between two
DNP haptens on neighboring arms of DF3 is ∼3.4 nm, although
the nine-amino acid linker has sufficient flexibility such that the
center-to-center distance between the two DNPs may vary between 2.7
and 6.2 nm. Configurations of antigen–IgE–FcεRI
aggregates can become increasingly complex, because each of the three
DNP haptens can engage one arm of an IgE–FcεRI complex
(Figure 1C). The variability in the distances
between Fabs would be expected to increase with the complexity of
the aggregate geometry. We speculate that there may be a narrow range
of distances that allow Lyn, when anchored on the β subunit
ITAM, to mediate trans phosphorylation of ITAMs in
adjacent FcεRI subunits. Differential spacing may also influence
the recruitment or composition of signaling protein complexes that
bind to phospho-ITAMs, including the enzymes Syk, SHIP, SHP-1, SHP-2,
PI3K, and PLCγ.[18,19] These considerations raise the
intriguing possibility that individual receptors within a complex
aggregate may make unequal contributions to FcεRI signaling.
The structural model predicts that bivalent binding of DF3 to both
Fab arms of the same IgE is not possible, which is a desirable feature
shared with other recently developed trivalent DNP ligands and tetravalent
ligands.[20] By comparison, DF3 is more symmetric
than published DNA-based ligands[14] and
more rigid than PEG-based ligands.[21] It
is noteworthy that structural modeling indicates DF3 also is capable
of forming cyclic receptor dimers (Figure 1C,D of the Supporting Information). Although cyclic dimers
can have limited signaling potential when engaged by bivalent ligands,[22] DF3 may not have the same limitations because
such dimers can be extended to form larger aggregates.
Figure 1
DF3, a new trivalent
ligand for mast cell secretion. (A) Three
monomers self-assemble to produce DF3, in which three DNP groups (red)
attached to the foldon peptide via a flexible linker (cyan) are symmetrically
arrayed. Top and side views are shown. On the basis of this model,
the linker length is ∼10 Å, the distance between any two
DNP groups is ∼34 Å, and the distance between any DNP
group and the center of the trimer is ∼17 Å. (B) Side
view of DF3 binding to one Fab arm (yellow and magenta for light and
heavy chains, respectively) of an IgE–FcεRI α (extracellular
domain, blue) complex. (C) Overhead view of one DF3 bound to three
IgE–FcεRI complexes. (D) Degranulation response in either
RBL-2H3 or bone marrow-derived mast cells, based on the percent of
total β-hexosaminidase released from cells after DF3 stimulation
for 30 min. Error bars represent the standard deviation. Data are
representative of three separate experiments each performed in duplicate.
DF3, a new trivalent
ligand for mast cell secretion. (A) Three
monomers self-assemble to produce DF3, in which three DNP groups (red)
attached to the foldon peptide via a flexible linker (cyan) are symmetrically
arrayed. Top and side views are shown. On the basis of this model,
the linker length is ∼10 Å, the distance between any two
DNP groups is ∼34 Å, and the distance between any DNP
group and the center of the trimer is ∼17 Å. (B) Side
view of DF3 binding to one Fab arm (yellow and magenta for light and
heavy chains, respectively) of an IgE–FcεRI α (extracellular
domain, blue) complex. (C) Overhead view of one DF3 bound to three
IgE–FcεRI complexes. (D) Degranulation response in either
RBL-2H3 or bone marrow-derived mast cells, based on the percent of
total β-hexosaminidase released from cells after DF3 stimulation
for 30 min. Error bars represent the standard deviation. Data are
representative of three separate experiments each performed in duplicate.
DF3 Stimulates Mast Cell
Secretion
Figure 1D reports the secretory
response of adherent RBL-2H3
cells (hereafter “RBL cells”) stimulated with DF3 over
a wide range of doses. This ligand induces ∼50% maximal degranulation,
a response that is more robust than the 20–30% responses observed
with DNA- and PEG-based trivalent ligands previously reported.[14,21] DF3-stimulated secretion exhibits a bell-shaped curve, which is
also seen for primary cells stimulated with antigen or anti-IgE.[23] Murine bone marrow-derived mast cells (BMMCs)
also exhibit dose-dependent secretory responses when challenged with
DF3 (Figure 1D), thus establishing the applicability
of DF3 to studying physiologically relevant mechanisms. The shift
in optimal DF3 concentration for BMMC secretion is likely due to ∼8-fold
differences in the ligand to receptor ratio utilized in the BMMC suspension
assay.
Modeling DF3 Binding
In addition to molecular scale
computations for estimating ligand–receptor docking, we adapted
the Goldstein–Perelson model[24] for
FcεRI cross-linking to provide further insight into aggregation
states of complexes formed after DF3 binding. We obtained a model
that reproduces the dose-dependent binding characteristics of DF35FAM, measured at equilibrium by flow cytometry (Figure 2A). According to the model, the shape of the binding
curve in Figure 2A is a consequence of the
interplay between the capture of free ligand and receptor cross-linking.
At low DF3 concentrations, bound ligands engage multiple receptors,
but most receptors are unbound. At sufficiently high concentrations,
ligands engage fewer receptors to the detriment of cross-linking,
and receptor binding approaches saturation. Parameters of the model
were determined through fitting.
Figure 2
Computational modeling and experimental
characterization of DF3
binding and FcεRI cross-linking. (A) Quality of fit. The solid
line is derived from the model in which each point along the curve
corresponds to the calculated number of bound ligands divided by the
total number of IgE antigen-combining sites (two per antibody) at
equilibrium for the indicated total ligand concentration. The filled
circles correspond to data from flow cytometric assays of the mean
fluorescence of cell-associated DF35FAM. Mean fluorescence
measurements (arbitrary units) have each been divided by a factor F of 227 (arbitrary units). (B) Cumulative probability analysis
(CPA) plots of diffusion coefficients derived from SPT experiments.
The mobility is largest for resting receptors (—), whereas
that of FcεRI cross-linked by 10 nM DF3 (···)
is smallest. (C) Computer simulations predict the fraction of FcεRI
in aggregates of specific sizes, determined at steady state after
exposure to doses of DF3 ranging from 0.01 to 300 nM. (D) Computer
simulations for the kinetics of mean aggregate size over time for
1, 10, and 300 nM DF3. (E) Mean fluorescence intensity of receptor
clusters in cells stimulated with DF35FAM for different
time periods. Bars represent the standard error of the mean of two
independent experiments.
Computational modeling and experimental
characterization of DF3
binding and FcεRI cross-linking. (A) Quality of fit. The solid
line is derived from the model in which each point along the curve
corresponds to the calculated number of bound ligands divided by the
total number of IgE antigen-combining sites (two per antibody) at
equilibrium for the indicated total ligand concentration. The filled
circles correspond to data from flow cytometric assays of the mean
fluorescence of cell-associated DF35FAM. Mean fluorescence
measurements (arbitrary units) have each been divided by a factor F of 227 (arbitrary units). (B) Cumulative probability analysis
(CPA) plots of diffusion coefficients derived from SPT experiments.
The mobility is largest for resting receptors (—), whereas
that of FcεRI cross-linked by 10 nM DF3 (···)
is smallest. (C) Computer simulations predict the fraction of FcεRI
in aggregates of specific sizes, determined at steady state after
exposure to doses of DF3 ranging from 0.01 to 300 nM. (D) Computer
simulations for the kinetics of mean aggregate size over time for
1, 10, and 300 nM DF3. (E) Mean fluorescence intensity of receptor
clusters in cells stimulated with DF35FAM for different
time periods. Bars represent the standard error of the mean of two
independent experiments.The structure of our model corresponds closely to that of
the equilibrium
continuum model of Goldstein and Perelson[24] for the interaction of a trivalent ligand with a bivalent cell-surface
receptor. The Goldstein–Perelson model, as well as our model,
accounts for all possible acyclic receptor aggregates, but as a simplification,
it omits cyclic aggregates, such as those illustrated in panels D
and E of Figure 1 of the Supporting Information. Because the quality of fit is excellent (Figure 2A), extending the model to incorporate cyclic aggregates is
not justified by the available data. However, we did find it necessary
to extend the structure of the Goldstein–Perelson model to
include immobilization of receptor aggregates above a threshold size
(see the Supporting Information). This
extension is consistent with the observed reduction in receptor mobility
upon ligand addition (Figure 2B). It also eliminates
the formation of a gel-like superaggregate, comparable to a “cap”
(i.e., a coalescence of immobile receptors into a localized region
of the cell surface),[8] which was not detected
experimentally. This supports the simplifying model assumption that
aggregates containing more than five receptors are not allowed to
interact with each other; free monomers and smaller aggregates may
join by diffusion.The histograms in Figure 2C show the predicted
fractions of receptors in monomeric and various aggregated states
for different DF3 doses at steady state. As can be seen, for a dose
of either 1 or 300 nM, at which secretory responses are poor (Figure 1D), at least 90% of the receptors are predicted
to be in clusters. The distribution of receptor aggregate sizes at
1 nM is similar to that at 10 nM, the optimal DF3 dose for degranulation.
At the supraoptimal dose of 300 nM, aggregates are smaller on average,
but the model still predicts the presence of aggregates containing
more than nine receptors. These results, which were subsequently confirmed
experimentally in EM experiments (Figure 3),
suggest that mast cell activation does not strictly correlate with
receptor aggregation and that the dose–response curves of Figure 1D are likely shaped by a balance of positive and
negative signaling.
Figure 3
DF3 induces dose-dependent FcεRI clusters on the
cell surface.
(A–C) TEM images of membrane sheets prepared from cells after
the FcεRI had been cross-linked for 5 min with 0, 10, or 300
nM DF3 and immunogold labeling (6 nm gold) for FcεRI β.
Arrows point to signaling patches, typical after addition of antigen.
The bar is 0.1 μm. (D) Plot of mean Hopkins test statistic values.
The bar indicates the group mean, while whiskers represent the entire
range of each group.
DF3 induces dose-dependent FcεRI clusters on the
cell surface.
(A–C) TEM images of membrane sheets prepared from cells after
the FcεRI had been cross-linked for 5 min with 0, 10, or 300
nM DF3 and immunogold labeling (6 nm gold) for FcεRI β.
Arrows point to signaling patches, typical after addition of antigen.
The bar is 0.1 μm. (D) Plot of mean Hopkins test statistic values.
The bar indicates the group mean, while whiskers represent the entire
range of each group.Our model, which was formulated through a rule-based approach
that
allows kinetic Monte Carlo simulations (Supporting
Information), can make predictions about the kinetics of ligand-induced
receptor aggregation (Figure 2D of the Supporting
Information). The model predicts that the initial rate of receptor
aggregate formation increases with ligand dose. However, at sufficiently
high doses, receptor aggregation is transient. This qualitative behavior
was confirmed experimentally in fluorescence microscopy experiments
(Figure 2E). Thus, high-dose stimulation of
mast cells entails significant receptor aggregation, even though the
level of aggregation at equilibrium is low. This behavior further
suggests that there is not a simple relationship between aggregation
and cell activation.
Single-Particle Tracking Indicates That DF3
Induces a Reduction
in Receptor Mobility
Previous observations indicate that
diffusion of antigen–IgE–FcεRI complexes is progressively
slowed as receptor aggregates grow in size.[25] Aggregates of two or three receptors have been shown to be nearly
as mobile as receptor monomers, whereas larger aggregates slow and
ultimately reach an essentially immobile state. For DF3, we also observed
this deceleration (Figure 2B) via established
single-particle tracking methods.[25,26] Quantum dot
(QD)-labeled IgE–FcεRI complexes aggregated with 10 nM
DF3 exhibited a marked shift in mobility (Figure 2B). Cross-linking of QD-labeled IgE–FcεRI complexes
with a supraoptimal concentration of DF3 (300 nM) led to enhanced
receptor slowing. The less dramatic deceleration at the higher ligand
dose suggests a smaller average aggregate size, which is consistent
with model predictions (Figure 2C).
Fluorescence
Imaging Reveals DF3 Dose-Dependent Kinetics of
IgE–FcεRI Aggregation
Our model predicts dose-dependent
differences in receptor aggregation kinetics (Figure 2D), which may correlate with mast cell outcomes. We sought
to experimentally validate the computational results using quantitative
fluorescence analysis of receptor clustering (Figure 2E). Cells were grown on glass coverslips, sensitized with
DNP-specific IgE, and incubated at 37 °C with a fluorescent ligand
(DF35FAM). At defined time intervals, cells were fixed,
mounted on glass slides, and imaged by wide field microscopy. 3D images
were deconvolved to minimize out-of-focus fluorescence emission and
spot intensities analyzed. In good agreement with model predictions,
a high DF3 dose (300 nM) led to a rapid increase in average cluster
intensity, which was followed by a decrease in intensity. The dose
optimal for degranulation (10 nM) elicited a slightly slower increase
in average cluster intensity, which reached a relatively higher level
and then persisted. The suboptimal dose of 1 nM elicited a markedly
slower increase in average cluster intensity, eventually approaching
the maximal intensity stimulated by the optimal dose. These data are
in qualitative agreement with our simulation results (compare Figure 2D,E; see also Supporting Information). We note that the experimental time courses for the 10 and 300
nM cases are closer to each other than the simulated time courses.
Simulations (not shown) indicate that this observation is to be expected
if small aggregates (e.g., receptor monomers and dimers) do not contribute
to the measured mean cluster intensity (i.e., are below the threshold
of detection). Taken together, it is clear that the antigen dose strongly
influences the kinetics of aggregate formation, as well as aggregate
size. Rapid but transient aggregate formation at high doses or delayed
formation of large aggregates seen in both simulations and experiments
could potentially lead to distinct patterns of recruitment of both
signaling and endocytic adaptors to FcεRI.
High-Resolution
EM Imaging Confirms DF3 Induces the Formation
of FcεRI Signaling Patches
Steady-state simulations
predict that most of the cell’s complement of 300000 receptors
could be cross-linked into small and large aggregates at low or high
doses of trivalent ligand that restrict degranulation. We next used
immunoelectron microscopy methods to characterize the redistribution
of FcεRI after exposure to DF3 at all doses considered. Native
membrane sheets were prepared from resting or stimulated RBL cells,
immunogold-labeled for FcεRIβ, and imaged by TEM.[4,27] As expected on the basis of earlier studies, we observed FcεRI
to be non-randomly distributed in the resting state (Figure 3A). For resting receptors, clustering is modest,
an indicator of FcεRI proximity, and not indicative of preformed
aggregates. Rather, these small clusters are thought to reflect transient
co-confinement of diffusing receptors in rafts and islands or corrals.[4,25] Images in panels B and C of Figure 3 show
that receptors accumulate in electron-dense regions of the membrane
at both the optimal (10 nM) and inhibitory (300 nM) doses of DF3.
An increase in the level of clustering at all doses of DF3 was confirmed
by applying the Hopkins spatial statistic test to a minimum of 10
images per data set. These results are summarized in Figure 3D, which indicates that an increase in the level
of receptor clustering is statistically significant for both optimal
(10 nM) and suboptimal (1 and 300 nM) doses.It is important
to emphasize that both fluorescence (Figure 2E) and electron microscopy (Figure 3) methods
do not provide direct measures of aggregation, because increases in
receptor density after activation are likely to reflect nearby aggregates
of various sizes that have coalesced into a “signaling patch”.[4] Thus, the computational model provides complementary
information and arguably a more precise estimate of the size distribution
of receptor aggregates.
DF3 Triggers a Differential, Dose-Dependent
Signal Initiating
Phosphorylation Events
Dose-dependent differences in phosphorylation
of proteins that trigger signal initiation in response to DF3 were
evaluated. Lysates were prepared from RBL cells challenged with either
1, 10, or 300 nM DF3. In Figure 4A, receptor
complexes were isolated by immunoprecipitation using anti-FcεRI
γ and β subunit antibodies, followed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
and Western blotting with pan-reactive anti-phosphotyrosine antibodies
or antibodies against ITAM-bearing β and γ subunits. To
evaluate Syk and Lyn phosphorylation, Western blots were probed with
phospho-specific antibodies. Results are plotted in Figure 4B, expressed as values normalized to either total
protein or β-actin. Phosphorylation of FcεRI subunits
and Syk continues to increase during stimulation for up to 5 min with
the optimal dose of DF3 (10 nM). Although phosphorylation of both
FcεRI subunits was markedly lower at low (1 nM) and high DF3
doses (300 nM), when compared to that at the optimal dose, the decrease
in γ phosphorylation was significantly greater (∼2–3-fold)
than that in β phosphorylation. Elevated β phosphorylation
at inhibitory doses most likely is linked to negative signaling, based
on previous studies that show its increased phosphorylation during
inhibitory signaling and association with negative signaling molecules
SHP-1 and SHIP.[28,29] Compared to that at an optimal
dose stimulus, Syk phosphorylation was reduced only ∼2-fold
at a high dose but was ∼7-fold lower after stimulation for
5 min at a low dose. Lyn dephosphorylation at the inhibitory site
Y507 was significantly reduced upon low-dose stimulation, whereas
high-dose stimulation led to a dephosphorylation rate similar to that
seen with the optimal dose.
Figure 4
Characterization of upstream and downstream
events in response
to DF3. (A) Tyrosine phosphorylation kinetics of FcεRI β
and γ subunits measured in anti-FcεRIγ and anti-FcεRIβ
immunoprecipitates and Syk346 and Lyn507 phosphorylation kinetics
measured in whole cell lysates. (B) Quantification of blots shown
in panel A, where normalized band intensities are plotted vs stimulation
time. (C) Fura-2-loaded individual cells were stimulated with DF3.
Ratio intensities (360/385) were measured and converted to [Ca2+] as described in Methods. (D) Internalization
of FcεRI measured by acid stripping of cells sensitized with
fluorescent IgE and stimulated with DF3. Confocal images show the
increase in internalized pools of fluorescent IgE over time. The plot
illustrates the kinetics of fluorescent IgE–FcεRI endocytosis,
as measured by flow cytometry. All data are representative of at least
two independent experiments.
Characterization of upstream and downstream
events in response
to DF3. (A) Tyrosine phosphorylation kinetics of FcεRI β
and γ subunits measured in anti-FcεRIγ and anti-FcεRIβ
immunoprecipitates and Syk346 and Lyn507 phosphorylation kinetics
measured in whole cell lysates. (B) Quantification of blots shown
in panel A, where normalized band intensities are plotted vs stimulation
time. (C) Fura-2-loaded individual cells were stimulated with DF3.
Ratio intensities (360/385) were measured and converted to [Ca2+] as described in Methods. (D) Internalization
of FcεRI measured by acid stripping of cells sensitized with
fluorescent IgE and stimulated with DF3. Confocal images show the
increase in internalized pools of fluorescent IgE over time. The plot
illustrates the kinetics of fluorescent IgE–FcεRI endocytosis,
as measured by flow cytometry. All data are representative of at least
two independent experiments.
Inhibition of Degranulation at Low and High DF3 Doses Correlates
with Calcium Responses and Is Not Due to Enhanced Clearance of Surface
Receptors
Results in Figure 4C show
that high and low doses of DF3 induce Ca2+ responses weaker
than that elicited by the optimal dose of DF3. In these experiments,
IgE-primed RBL cells were preloaded with Fura-2 AM, followed by single-cell,
ratio imaging microscopy during antigen challenge. A typical response
to 10 nM DF3 is a rapid spike in the intracellular calcium concentration
followed by an oscillatory sustained phase. By comparison, calcium
responses to 1 or 300 nM DF3 typically exhibited a weak or absent
initial spike, followed by oscillations that return almost to baseline
in the intervals. Because mast cell secretion is calcium-dependent,
these results are consistent with poor degranulation at suboptimal
ligand doses.Finally, Figure 4D reports
results of experiments designed to test the possibility that low and/or
high doses of DF3 might result in more extensive clearance of receptors
from the cell surface, which could theoretically limit sustained signaling.
The assay is illustrated in the images in Figure 4D, where cells were sensitized with IgE-Alexa647, incubated with the DF3 ligand at 37 °C to permit internalization,
and then briefly exposed to an acidic wash at 4 °C to strip off
surface IgE. The image at the top left reports levels of red fluorescent
IgE bound to resting cells in the absence of an acid wash. For quantification,
identical samples were processed for flow cytometry, with and without
acid stripping. The results show that, contrary to the possibility
of a greater level of endocytosis at high doses, only ∼15%
of receptors are endocytosed after incubation with 300 nM ligand.
This endocytosis occurs within the first 2 min, followed by cessation
of further internalization. This is consistent with the model predictions
in Figure 2, where continued binding of excess
ligand reduces the size of aggregates but does not ablate them. By
comparison, endocytosis does not slow dramatically until 10 min at
the optimal dose of the trivalent ligand (10 nM DF3). The lowest dose
(1 nM) of the ligand supports endocytosis for up to 20 min, achieving
the highest total level of internalization at ∼50%. Thus, the
lowest dose of ligand, which is a poor degranulating stimulus, clearly
triggers the post-translational modifications (phosphorylation and
ubiquitination) that are associated with immunoreceptor endocytosis.[30]It is notable that other trivalent and
bivalent ligands fail to
cause measurable internalization upon FcεRI cross-linking.[14,31] This suggests that, in addition to aggregate size, structural aspects
of antigens other than valency are important factors in endocytosis.
These factors remain unknown but could include the distance between
antigen binding sites or the flexibility of the carrier.
SHIP Colocalizes
with Resting and Activated FcεRI, with
Enhanced Kinetics at Inhibitory Doses
The persistence of
substantially sized receptor clusters (which likely represent groups
of aggregates) at inhibitory doses is confirmed by our EM studies.
On the basis of this observation, we hypothesized that positive signaling
is being counteracted by negative signaling at these doses, perhaps
by the recruitment of phosphatases. The inositol phosphatase SHIP
has been previously shown to downregulate FcεRI signaling at
supraoptimal antigen concentrations.[32] Therefore,
we next evaluated its colocalization with FcεRI under resting
and stimulated conditions. Images in Figure 5 illustrate this protocol, where membrane sheets were immunogold-labeled
using antibodies to phospho-SHIP (5 nm gold) and FcεRI (10 nm
gold) and imaged by TEM. This high-resolution imaging method reveals
dose-dependent coclustering of phospho-SHIP with FcεRI β.
We found that, although the label for phospho-SHIP is relatively sparse
in resting cells, where it is found it is consistently colocalized
with resting FcεRI (arrows, Figure 5A,
left). As the stimulus proceeds, additional phospho-SHIP accumulates
on cell membranes, where it largely colocalizes with receptor signaling
patches (small gold particles, Figure 5A).
Remarkably, as shown, the extent of phospho-SHIP colocalization with
FcεRI showed different kinetics for three doses of DF3. Treatment
groups were found to be statistically different using a one-way analysis
of variance (ANOVA) test (p = 4.54 × 10–8). For both suboptimal (1 nM) and supraoptimal (300
nM) doses, accumulation of phospho-SHIP was most notable at 2 min.
In contrast, phospho-SHIP colocalization with receptors at 2 min at
the optimal dose was low [10 nM (Figure 5B)],
increasing to more significant levels at 5 min.
Figure 5
Dose-dependent role of
SHIP in FcεRI signaling. (A) TEM images
of membrane sheets prepared from cells after the FcεRI had been
cross-linked for 2 min with indicated doses of DF3 and immunogold
labeling for SHIP (6 nm gold) and FcεRI β (12 nm gold).
Arrows point to coclusters of SHIP and FcεRI β. The bar
is 0.1 μm. Images are accompanied by their Ripley’s bivariate
test results. (B) Gold particles marking SHIP were scored for coclustering
with FcεRI β in membrane sheets from resting cells and
cells stimulated for 2 and 5 min. At least 2000 gold particles were
counted for each experimental condition. The asterisk indicates clustering
is statistically different between any two doses at 2 min. (C) Membrane
recruitment of phospho-SHIP with the DF3 stimulus. Cells were stimulated,
followed by fractionation to yield crude membrane fractions. Samples
were separated by SDS–PAGE and immunoblotted with the anti-phospho-SHIP
antibody. (D) Proximity ligation assay confirming the interaction
of phospho-SHIP with the β subunit of FcεRI. The fluorescent
signal was measured in RBL-2H3 cells overexpressing chimeric FceRI β
either under basal conditions or by cross-linking the chimeric receptor,
and basal or stimulated (10 nM DF3) wild-type RBL-2H3 cells. Results
are representative of two independent experiments. (E) Western blot
confirming 60% knockdown of Lyn or 10-fold overexpression of Lyn in
RBL-2H3 cells. (F) Proximity ligation assay measuring phospho-SHIP
and β interaction in either Lyn knockdown (KD) or Lyn overexpression
(O/X) cells stimulated with 10 nM DF3. Results are representative
of two independent experiments. (G) Degranulation response in RBL-2H3
cells with Lyn KD, based on the percent of total β-hexosaminidase
released from cells after stimulation with indicated doses of DF3
for 30 min. Error bars represent the standard deviation. Results are
representative of at least two independent experiments.
Dose-dependent role of
SHIP in FcεRI signaling. (A) TEM images
of membrane sheets prepared from cells after the FcεRI had been
cross-linked for 2 min with indicated doses of DF3 and immunogold
labeling for SHIP (6 nm gold) and FcεRI β (12 nm gold).
Arrows point to coclusters of SHIP and FcεRI β. The bar
is 0.1 μm. Images are accompanied by their Ripley’s bivariate
test results. (B) Gold particles marking SHIP were scored for coclustering
with FcεRI β in membrane sheets from resting cells and
cells stimulated for 2 and 5 min. At least 2000 gold particles were
counted for each experimental condition. The asterisk indicates clustering
is statistically different between any two doses at 2 min. (C) Membrane
recruitment of phospho-SHIP with the DF3 stimulus. Cells were stimulated,
followed by fractionation to yield crude membrane fractions. Samples
were separated by SDS–PAGE and immunoblotted with the anti-phospho-SHIP
antibody. (D) Proximity ligation assay confirming the interaction
of phospho-SHIP with the β subunit of FcεRI. The fluorescent
signal was measured in RBL-2H3 cells overexpressing chimeric FceRI β
either under basal conditions or by cross-linking the chimeric receptor,
and basal or stimulated (10 nM DF3) wild-type RBL-2H3 cells. Results
are representative of two independent experiments. (E) Western blot
confirming 60% knockdown of Lyn or 10-fold overexpression of Lyn in
RBL-2H3 cells. (F) Proximity ligation assay measuring phospho-SHIP
and β interaction in either Lyn knockdown (KD) or Lyn overexpression
(O/X) cells stimulated with 10 nM DF3. Results are representative
of two independent experiments. (G) Degranulation response in RBL-2H3
cells with Lyn KD, based on the percent of total β-hexosaminidase
released from cells after stimulation with indicated doses of DF3
for 30 min. Error bars represent the standard deviation. Results are
representative of at least two independent experiments.Biochemical experiments were performed to confirm
the rapid recruitment
of phospho-SHIP to the membrane with sub- and supraoptimal doses of
DF3 (Figure 5C). A simple cell fractionation
experiment revealed the presence of phospho-SHIP at the membrane upon
the DF3 stimulus for 2 min with inhibitory doses, but not with the
optimal dose.It is important to note that both the EM and membrane
fractionation
methods strongly indicate the recruitment of SHIP to receptor signaling
patches but do not report the direct interaction of proteins. In addition
to FcεRI subunits,[33] SHIP has several
other potential docking partners, including adaptor proteins such
as Shc, Grb2, and Dok.[34,35] SHIP can also be recruited to
PI(3,4)P2 via its C2 domain.[36] We next
used the proximity ligation assay (PLA) in RBL cells transfected with
a chimeric receptor composed of the extracellular and transmembrane
domains of the IL-2 α subunit (Tac antigen) joined to the cytoplasmic
domain of the FcεRI β subunit;[37] this construct is termed TTβ. Transfected cells were fixed
before or after TTβ had been cross-linked with anti-Tac antibodies,
permeabilized, and incubated with primary antibodies against SHIP
and FcεRI β that were conjugated with the paired PLA probes.
Following ligation and amplification, fluorescent oligonucleotide
probes were imaged and quantified as spots by confocal imaging. Results
in Figure 5D show that TTβ cross-linking
led to the significant recruitment of SHIP to the chimeric β
receptor, providing evidence that SHIP and β likely interact
or are part of a complex, given their proximity (<40 nm) as detected
by PLA.Figure 5D also shows results
of the PLA
after cross-linking of IgE–FcεRI complexes with DF3 in
RBL cells. Like the isolated chimeric β, phospho-SHIP is recruited
to the intact receptor after cross-linking (compare images in basal
and simulated wild-type RBL cells). Because Lyn is principally responsible
for β ITAM phosphorylation[37] and
also a potential binding partner for SHIP,[34] we also compared results of the PLA in cells overexpressing Lyn
(Lyn O/X in Figure 5F) to results in cells
treated with siRNA to knock down Lyn (Lyn KD in Figure 5F). Results show that the recruitment of phospho-SHIP to FcεRI
β is strongly dependent on Lyn: the level is dramatically increased
upon Lyn overexpression and significantly reduced upon Lyn knockdown
in RBL cells. Western blots in Figure 5E show
the comparative levels of Lyn in wild-type (WT), Lyn KD, and Lyn O/X
cells. Finally, the link between Lyn and negative regulation of secretion
is illustrated in Figure 5G, where Lyn knockdown
(60%) results in a significant increase in the level of DF3-stimulated
degranulation over a wide range of doses.It is intriguing to
speculate that incomplete ITAM phosphorylation
may be the reason that aggregates induced at low or supraoptimal doses
favor faster SHIP recruitment, but reduced Syk activity. This hypothesis
is based upon the recent study by Cambier and colleagues, who showed
that monophosphorylation of Igα and Igβ ITAMs drive the
activation of SHIP-Dok circuitry to cause anergy in B cells.[38] SHIP, with its single SH2 domain, is favored
for recruitment to monophosphorylated ITAMs over Syk, which has two
SH2 domains that interact with dually phosphorylated FcεRI γ
ITAM. New reagents are needed to evaluate the mono- and biphosphorylation
status of FcεRI β/γ ITAMs after the DF3 stimulus.
This is an important future direction, because monophosphorylation
is a reasonable mechanism for the conversion of a positive signaling
ITAM to an inhibitory one (ITAMi). The phenomenon of inhibitory signaling
from other FcR has been described recently, including the formation
of “inhibisome” clusters that also recruit protein phosphatase
SHP-1.[39]
The Dose–Response
Curve for Degranulation Is Differentially
Regulated by Protein/Inositol Phosphatases
FcεRI signal
initiation, including activation of SHIP and Syk, is regulated by
protein tyrosine phosphatases. The closely related protein tyrosine
phosphatases, SHP-1 and SHP-2, have been described as negative and
positive effectors of FcεRI activation. Although both bind to
FcεRI and affect phosphorylation events downstream, no significant
changes in mast cell degranulation have been previously reported.[40,41] We assessed the effect of SHIP, SHP-1, and SHP-2 knockdown on degranulation
responses to a wide range of DF3 doses. The Western blot in Figure 6A shows that treatment with specific siRNA for 24
h was optimal for lowering endogenous levels of SHIP, SHP-1, and SHP-2
by 70–90%. The knockdown of both SHIP and SHP-1 produced a
marked increase in the level of mast cell degranulation across all
doses of DF3 (Figure 6B). With a 30 min stimulus,
results show that the most dramatic enhancement of degranulation was
at the suboptimal dose of 1 nM, with a >6-fold increase in response
seen with SHIP KD and an ∼3-fold increase in response to SHP-1
KD after stimulation for 30 min.
Figure 6
Positive and negative regulators of mast
cell signaling. (A) Western
blot confirming the 75, 90, and 71% knockdown of SHIP, SHP-1, and
SHP-2, respectively. (B) Degranulation response after DF3 stimulation
for 30 min in RBL-2H3 cells knocked down for SHIP and SHP-1. (C) Degranulation
response or fold change in secretion in RBL-2H3 cells knocked down
for SHIP after stimulation for 10 or 30 min. (D) Degranulation response
after stimulation for 30 min in RBL-2H3 cells knocked down for SHP-2
(C). Degranulation values in panels B–D are based on the percent
of total β-hexosaminidase released from cells after stimulation
with the indicated doses of DF3. Error bars represent the standard
deviation. Results are representative of three independent experiments.
(E and F) Tyrosine phosphorylation kinetics of Syk346 measured in
whole cell lysates from WT, SHP-1, and SHP-2 KD cells stimulated with
10 nM DF3. Results are representative of three independent experiments.
(G) Quantification of the fluorescent signal from PLA for the Lyn–FcεRI
β interaction in WT and SHP-2 KD cells. Bars represent the standard
deviation of mean fluorescent spots counted from at least 80 cells
(n), from seven fields of view. Results are representative
of two independent experiments.
Positive and negative regulators of mast
cell signaling. (A) Western
blot confirming the 75, 90, and 71% knockdown of SHIP, SHP-1, and
SHP-2, respectively. (B) Degranulation response after DF3 stimulation
for 30 min in RBL-2H3 cells knocked down for SHIP and SHP-1. (C) Degranulation
response or fold change in secretion in RBL-2H3 cells knocked down
for SHIP after stimulation for 10 or 30 min. (D) Degranulation response
after stimulation for 30 min in RBL-2H3 cells knocked down for SHP-2
(C). Degranulation values in panels B–D are based on the percent
of total β-hexosaminidase released from cells after stimulation
with the indicated doses of DF3. Error bars represent the standard
deviation. Results are representative of three independent experiments.
(E and F) Tyrosine phosphorylation kinetics of Syk346 measured in
whole cell lysates from WT, SHP-1, and SHP-2 KD cells stimulated with
10 nM DF3. Results are representative of three independent experiments.
(G) Quantification of the fluorescent signal from PLA for the Lyn–FcεRI
β interaction in WT and SHP-2 KD cells. Bars represent the standard
deviation of mean fluorescent spots counted from at least 80 cells
(n), from seven fields of view. Results are representative
of two independent experiments.The kinetics of clustering and internalization were shown
above
to differ markedly across suboptimal and supraoptimal doses. Thus,
dose-dependent differences in the kinetics of degranulation were also
evaluated by measuring degranulation responses after SHIP knockdown
and shorter exposures to DF3 (Figure 6C). The
fold increase in secretion at 300 nM was marked in SHIP KD cells with
a 10 min stimulus, consistent with the rapid rise in the recruitment
of SHIP to FcεRI signaling patches at this high dose (Figure 5B).Inhibition of calcium responses and degranulation
by SHIP has been
shown previously,[32] consistent with a role
for its substrate PIP3 (phosphatidylinositol-3,4,5-P3) as an allosteric
activator of PLCγ isoforms in mast cells.[42] The regulation of SHIP’s own activity is somewhat
ambiguous. We found that changes in SHIP phosphorylation were modest
over all doses of DF3 (data not shown). This suggests that membrane
recruitment, measured here by TEM and by PLAs, is a critical readout
of SHIP activation. Allosteric regulation of SHIP[36] during this recruitment may also play an important role.Contrary to SHP-1, knockdown of SHP-2 significantly decreases the
degranulation response across all doses (Figure 6D), thus demonstrating its opposing role as a positive regulator
of mast cell responses. Lowering SHP-2 levels led to a sustained reduction
in the level of Syk phosphorylation (Figure 6E,F) as well as a modest but statistically significant (p < 0.03) reduction in the level of interaction of Lyn with FcεRI
β (Figure 6G). As discussed further below,
these data underscore the dual roles for Lyn in FcεRI signaling.
Lyn is required to accelerate ITAM phosphorylation for the recruitment
and activation of Syk, a step that is influenced by SHP-2. As a negative
regulator, Lyn is critical for recruiting SHIP to FcεRI and
likely linked to SHP-1.
Summary and Conclusions
In this
study, we have characterized
a novel trivalent ligand, DF3, which triggers robust and dose-dependent
mast cell responses by efficiently cross-linking the IgE–FcεRI
complexes. The variability in distance between cross-linked receptors
predicted by structural modeling suggests increased complexity in
aggregate geometry could influence the recruitment of downstream signaling
proteins. Using both experimental and computational approaches, we
characterized dose-dependent receptor aggregate properties and observed
the persistence of large receptor aggregates even at inhibitory doses.
Furthermore, we observe dose-dependent differences in the kinetics
of receptor aggregation that lead to the equilibrium state. On the
basis of these observations, we hypothesized that reduced mast cell
responses with suboptimal dose stimulation are caused by a shift in
the activation of positive and negative signaling, causing preferential
recruitment of phosphatases over Syk to FcεRI. At the optimal
dose, receptor clusters are capable of overriding negative signaling
by primarily recruiting Syk. Support for this hypothesis comes from
the observation that Syk is weakly phosphorylated, whereas the inositol
phosphatase SHIP is more rapidly recruited to the receptor, at inhibitory
doses of 1 and 300 nM. This is potentially caused by ITAM monophosphorylation.[38]RNAi-mediated studies were performed to
characterize the role of phosphatases SHIP, SHP-1, and SHP-2 in regulating
mast cell responses. Interestingly, in our study, both SHIP and SHP-1
were shown to negatively regulate degranulation across all doses.
Knockdown of SHP-1 leads to increased Syk phosphorylation over time.
On the other hand, SHP-2 knockdown causes significant reduction in
both the degranulation response and Syk phosphorylation. Thus, SHP-1
and SHP-2 are key phosphatases that tune the secretory response, potentially
by regulating SHIP and Syk signaling loops, respectively. Our results
demonstrate that optimal secretory responses of mast cells and basophils
depend on the formation of receptor aggregates capable of overriding
negative regulatory signals. Future studies are required to better
understand how different aggregate sizes tip the balance of positive
and negative signaling.
Methods
Additional details
about the experimental and computational methods
may be found in the Supporting Information.
DF3 Synthesis and Purification
The trivalent ligand
was synthesized by AnaSpec. Briefly, Fmoc-Lys(5-Mtt)-OH was loaded
onto HMP resin, followed by treatment with 20% piperidine in DMF to
generate H-Lys(Mtt)-HMP resin. Peptide assembly was completed by sequentially
coupling each designated Fmoc-AA(xx)-OH in an HCTU/NMM/DMF mixture
and de-Fmoc using 20% piperdine in DMF. The resin was split into two
portions to produce either the unmodified (dark) peptide or a variant
with a fluorescent (5FAM) tag at the COOH terminus. After the last
Fmoc-Lys(DNP)-OH coupling, the Mtt protecting group of Lys(Mtt) was
removed with a 1% TFA cocktail and N-teminal Fmoc was removed with
20% piperidine in DMF. Treatment with cleavage cocktail released the
crude peptide, which was purified by preparative reversed phase high-performance
liquid chromatography and lyophilized.
Degranulation, Western
Blotting, Internalization, Membrane Fractionation,
and EM Assays
Cell monolayers were grown in 24-well tissue
culture plates for 24 h and sensitized with 5 nM IgEDNP. Measurement of β-hexosaminidase release and immunoblotting
were performed as described previously.[43] Internalization of IgE–FcεRI complexes was measured
by a previously described acid stripping protocol and flow cytometry.[25] Fluorescent images of cells stimulated with
DF35FAM were taken on an inverted Olympus IX71 microscope
using a 150× objective lens. Membrane fractionation was performed
as previously described.[44] Methods for
the preparation of mast cell membrane sheets and immunogold labeling
FcεRI have been described.[27] Digital
images were acquired using a Hitachi H600 transmission electron microscope,
followed by image processing to capture the FcεRI gold particle
distribution and use of published methods for statistical analysis
of clustering.[45] Statistical differences
were also computed using a one-way ANOVA test in MATLAB (version 8.0.0,
The MathWorks).
Flow Cytometry-Based Binding Assays
Suspensions of
sensitized RBL cells (2 × 106 cells/mL) were incubated
at room temperature with DF35FAM at doses ranging from
0.01 to 1000 nM while the mixture was gently shaken. After 1 h, the
mean fluorescence (520 nm) was measured on a Becton Dickinson FACScan
flow cytometer, controlled with Cell Quest software. The fluorescence
of nonsensitized cells, incubated with a fluorescent ligand under
identical conditions, served as a baseline control for nonspecific
binding.
Single-Particle Tracking
Experiments
were performed
using functionally monovalent QD-IgE,[26,46] and analysis
of single-quantum dot tracking was performed as previously described.[46] Diffusion coefficients (D1–3) were determined by fitting the first three points
of the mean squared displacement (MSD) plots to the equation MSD =
offset + 4D1–3Δt;[47] the median D for
all trajectories under each treatment condition is reported, and the
distribution of values can be seen in the cumulative probability analysis
plot.
Calcium Measurements
Cells were loaded with Fura-2
AM for 30 min before being washed and observed on an inverted Olympus
IX71 microscope, equipped with a Til Monochromator (TILL Photonics).
Excitation light alternately passed through 10 nm band-pass filters
centered at 350 and 380 nm; emission was collected with a 510 nm WB
40 filter (Omega Optical). Images were acquired with an Andor iXon
EM-CCD camera and reagents added by manual micropipet. Ratio values
for each cell in a field were calculated for user-defined regions
after background subtraction and converted to [Ca2+] using
the Fura-2calcium imaging calibration kit. Analysis was performed
using ImageJ[48] and Prism (GraphPad Software).
Clustering Analysis
Stimulated cells were fixed and
imaged with an inverted Olympus 1X71 instrument (Mercury fluorescence
lamp), with a 150× oil objective. Images were deconvolved using
Huygens Essential software, and the top few slices of each cell were
used for analysis. Roughly 20 cells per treatment group were used
for analysis. Image analysis was performed using a custom script written
in MATLAB (version 8.0.0, The MathWorks).
Proximity Ligation Assays
Cells grown on coverslips
were stimulated with DF3, fixed with 2% PFA, and permeabilized with
0.1% Triton-X in PBS. Cells were blocked in 3% BSA (in PBS) and incubated
with primary antibodies at a 1:100 dilution in blocking buffer for
1 h. To detect the proximity between two proteins, complementary secondary
probes (PLUS and MINUS) binding the primaries raised in different
species were added to cells at a 1:5 dilution in blocking buffer for
60 min at 37 °C. Subsequent detection of the proximity of bound
probes was performed with an in situ PLA detection
kit (Olink), as per the manufacturer’s instructions. Cells
were imaged with an LSM510 META confocal microscope. PLA signals represented
by individual punctas were quantified using Omero.[49] Statistical differences were computed using a Student’s t test.
Nucleofection of siRNAs
RBL-2H3
cells were transfected
with Qiagen Flexi Tube siRNA for rat SHIP, SHP-1, and SHP-2 or Lyn
SmartPool siRNA from Dharmacon. The Amaxa Nucleofector and Cell Line
Nucleofector kit T (Lonza Cologne GmbH) were utilized according to
the manufacturer’s protocol. Cells were transfected with 0.25–0.5
μg of siRNA per 1 million cells and plated in regular growth
medium. The cultures were allowed to rest for 24 h before experiments
were performed and the efficiency of knockdown was determined via
immunoblot analyses.
Computational Modeling of Structures and
Ligand–Receptor
Binding
Structural models of ligand-induced receptor aggregates
were built using the motif binding geometry method,[50] homology modeling, and molecular dynamics. A model for
IgE bound simultaneously to FcεRIα and DNP was constructed
on the basis of available structures [Protein Data Bank (PDB) entries 1OAU, 2VWE, 1O0V, and 1F6A] and knowledge of
how these molecules interact. The structure of the trimeric foldon
is known (PDB entry 1RFO). The structure of the linker peptide used to connect the foldon
to DNP was determined using an algorithm for modeling protein loops
with fixed ends.[51] Our model for the interaction
of DF3 with cell-surface IgE was formulated in terms of local rules
and simulated as described previously.[8] A novel aspect of the model is a negative application condition
that prohibits interactions between aggregates containing more than
a threshold number of receptors. Additional details about the model
and a description of how parameters were estimated on the basis of
equilibrium binding data are given in the Supporting
Information.
Authors: C L Kepley; J C Cambier; P A Morel; D Lujan; E Ortega; B S Wilson; J M Oliver Journal: J Allergy Clin Immunol Date: 2000-08 Impact factor: 10.793
Authors: Sarah Güthe; Larisa Kapinos; Andreas Möglich; Sebastian Meier; Stephan Grzesiek; Thomas Kiefhaber Journal: J Mol Biol Date: 2004-04-02 Impact factor: 5.469
Authors: B S Wilson; N Kapp; R J Lee; J R Pfeiffer; A M Martinez; Y Platt; F Letourneur; J M Oliver Journal: J Biol Chem Date: 1995-02-24 Impact factor: 5.157
Authors: Avanika Mahajan; Lama A Youssef; Cédric Cleyrat; Rachel Grattan; Shayna R Lucero; Christopher P Mattison; M Frank Erasmus; Bruna Jacobson; Lydia Tapia; William S Hlavacek; Mark Schuyler; Bridget S Wilson Journal: J Immunol Date: 2016-12-30 Impact factor: 5.422
Authors: Brooke Harmon; Lily A Chylek; Yanli Liu; Eshan D Mitra; Avanika Mahajan; Edwin A Saada; Benjamin R Schudel; David A Holowka; Barbara A Baird; Bridget S Wilson; William S Hlavacek; Anup K Singh Journal: Sci Rep Date: 2017-11-14 Impact factor: 4.379
Authors: Binh L Phong; Lyndsay Avery; Tina L Sumpter; Jacob V Gorman; Simon C Watkins; John D Colgan; Lawrence P Kane Journal: J Exp Med Date: 2015-11-23 Impact factor: 14.307